This article is published with digital features, including a graphical plain language summary, to facilitate understanding of the article. To view digital features for this article, go to https://doi.org/10.6084/m9.figshare.25407607 .
Glycemic management through appropriate modifications of nutrition, exercise, and medications is of critical importance in preventing complications associated with type 2 diabetes mellitus [ 1 – 3 ]. Lifestyle modifications, including intensive …
Tirzepatide is a once-weekly dual agonist to glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors which is currently FDA-approved for the treatment of type 2 diabetes and obesity [ 1 ]. A few recent …
Authors:
Kagan E. Karakus, Matthew P. Klein, Halis K. Akturk, Viral N. Shah
Despite insulin being a lifesaving medication, insulin distress, insulin hesitancy, and insulin inertia remain oft-repeated themes in diabetes discourse. The current model lists three issues: temperament, troublesomeness, and technicality, which …
Diabetes is a chronic disease that affects 537 million adults worldwide, or 1 in 10 people, and it is expected to increase to 643 million by 2030 [ 1 ]. This chronic condition requires continuous effort from the individual to manage their treatment …
Authors:
Núria Alonso-Carril, Silvia Rodriguez-Rodríguez, Carmen Quirós, Belén Berrocal, Antonio J. Amor, Maria-José Barahona, Davinia Martínez, Carme Ferré, Verónica Perea
Practical advice on how to use tirzepatide in the management of type 2 diabetes, according to the clinical profile and therapeutic goals. Learn about adverse events, special warnings, precautions, and more.
Authors:
Luis A. Vázquez, Santiago Tofé-Povedano, Diego Bellido-Guerrero, Marta Botella-Serrano, Alfonso Soto-González, Pedro Mezquita-Raya, Elías Delgado, Carmen Fajardo-Montañana, Cristóbal Morales-Portillo, Ana Causanilles, Miriam Rubio-de Santos, Irene Romera, Esteban Jódar-Gimeno
Open Access
09-05-2024 | Semaglutide | Original Research
Diabetes mellitus affects one in ten Americans, with 90‒95% of patients with diabetes diagnosed with type 2 diabetes mellitus (T2DM) [ 1 ]. T2DM rarely occurs on its own and is typically associated with a host of comorbid conditions. Comorbidities …
Authors:
Caroline Swift, Monica S. Frazer, Noelle N. Gronroos, Andrew Sargent, Michael Leszko, Erin Buysman, Sara Alvarez, Tyler J. Dunn, Josh Noone, Mico Guevarra
Open Access
09-05-2024 | Semaglutide | Brief Report
Clinical interest in therapies for people with type 2 diabetes (T2D) has prospered in the last decade with many demonstrating a major impact beyond glycemic control. In clinical trials, at least, glucagon-like peptide-1 receptor analogues …
Authors:
David M. Williams, Barbara-Alex Alberts, Asem Sharaf, Giselle Sharaf, Stephen C. Bain, Atul Kalhan, Thinzar Min
Open Access
08-05-2024 | Type 2 Diabetes | Original Research
Current treatment guidelines for type 2 diabetes mellitus (T2DM) currently recommend the use of incretin-based therapies as first-line injectable treatment, but many people with T2DM will require insulin at some point during the course of their …
Authors:
Alex Ramírez-Rincón, Diana Henao-Carrillo, Miguel Omeara, Julio Oliveros, José Assaf, Jaime E. Ordóñez, Preethy Prasad, María Alejandra Alzate
In this podcast, we discuss the 2023 update of the International Working Group on the Diabetic Foot (IWGDF) Guidelines on the prevention of foot ulcers in people with diabetes. Prevention of foot ulcers is paramount, to reduce their large burden …
In this Adis podcast, the guideline’s lead authors highlight why offloading treatments are needed, what the updated guideline recommends, and what the offloading future could bring.
The podcast and transcript can be viewed below the abstract of the online version of the manuscript. Alternatively, the podcast can be downloaded here: https://doi.org/10.6084/m9.figshare.24793452 .
